Investment Thesis
Soligenix is in financial distress with revenue collapsed 85.8% YoY to $119.4K while operating losses of $2.9M persist, resulting in an unsustainable -$2.4M operating cash burn. At the current burn rate, the company's $6.0M cash runway extends only 2-3 quarters without revenue stabilization or significant operational restructuring.
Strengths
- Zero long-term debt eliminates leverage risk
- Gross margin of 81.5% indicates viable product economics if revenue returns
- Current ratio of 1.81x provides adequate short-term liquidity buffer
Risks
- Revenue cliff of -85.8% YoY represents loss of primary business operations
- Negative operating cash flow of -$2.4M per period indicates unsustainable cash depletion
- Operating losses of -$2.9M against $119.4K revenue signals operational unviability
- Zero insider Form 4 filings in 90 days reflects no insider confidence
- Pharmaceutical company with near-zero revenue faces existential viability questions
- Cash runway of 2-3 quarters at current burn rate without intervention
Key Metrics to Watch
- Quarterly revenue stabilization and recovery trajectory
- Monthly cash burn rate and runway extension
- New product launches or pipeline progression announcements
- Strategic alternatives or restructuring announcements
- Changes in insider shareholding activity
Financial Metrics
Revenue
119.4K
Net Income
-2.8M
EPS (Diluted)
$-0.28
Free Cash Flow
-2.4M
Total Assets
6.9M
Cash
6.0M
Profitability Ratios
Gross Margin
81.5%
Operating Margin
-2,416.7%
Net Margin
-2,366.5%
ROE
-91.4%
ROA
-40.8%
FCF Margin
-1,980.1%
Balance Sheet & Liquidity
Current Ratio
1.81x
Quick Ratio
1.81x
Debt/Equity
0.00x
Debt/Assets
55.4%
Interest Coverage
-6.49x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:45:26.449567 |
Data as of: 2026-03-31 |
Powered by Claude AI